Skip to search formSkip to main contentSkip to account menu

etelcalcetide

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Experience of Secondar y Hyperparathyroidism with Etelcalcetide in Hemodialysis Patients The Tolerance and Safety after Switching from the 25 mg of Cinacalcet to the 5 mg of Etelcalcetide
Background：We have reported on the administration of PARSABIV®（hereinafterreferred to as etelcalcetide）to patients with… 
2018
2018
Efektivitas Etelcalcitide terhadap Hiperparatiroidisme Sekunder Pada Pasien Gagal Ginjal Kronik
Secondary hyperparathyroidism (sHPT) is a frequently occurring severe complication of advanced kidney disease. Its clinical… 
Review
2018
Review
2018
Etelcalcetide is an innovative drug for the treatment of secondary hyperparathyroidism in patients on programmed hemodialysis (literature review)
2018
2018
Efficacy and safety of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism: Real life data
2018
2018
Es el etelcalcetide un fármaco seguro y eficaz para el tratamiento del hiperparatiroidismo secundario en pacientes en hemodiálisis
2017
2017
A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
AIMS To evaluate dose-escalation of etelcalcetide (ONO-5163/AMG 416), a novel, intravenous (IV), long-acting calcium-sensing… 
2017
2017
Kalzimimetika und Vitamin D
ZusammenfassungDie medikamentöse Therapie des sekundären Hyperparathyreoidismus (sHPT) bei chronischer Nierenerkrankung („chronic… 
2016
2016
MP361EFFICACY AND SAFETY OF A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE) IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM : RESULTS OF A PLACEBO CONTROLLED PHASE III…
2016
2016
MP368A NOVEL INTRAVENOUS CALCIMIMETIC, ONO-5163 (ETELCALCETIDE): A MULTICENTER, SINGLE AND MULTIPLE DOSE STUDY IN JAPANESE HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM